Expression of TIMP2 has been identified in individual studies as prognostic biomarkers in established and locally advanced colorectal cancer.
| Inventor | Institute |
|---|---|
| Ayham Alnabulsi | Vertebrate Antibodies Limited |
| SKU: | 151837 |
|---|---|
| Product description: | Matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix (ECM) in normal physiological processes as well as in disease processes. Tissue inhibitors of metalloproteinases (TIMPs) are the main physiological regulators of the MMPs. The TIMPs are secreted proteins that complex with individual MMPs and regulate the activity of specific MMPs. Together, the MMPs and TIMPs form a complex biological system strictly controlling degradation of ECM. The MMPs and TIMPs have a significant role in facilitating tumour invasion and metastasis. Expression of TIMP2 has been identified in individual studies as prognostic biomarkers in established and locally advanced colorectal cancer. |
| Conjugation: | Unconjugated |
| Isotype: | IgG2b |
| Immunogen: | Ovalbumin-conjugated synthetic peptide; DSGNDIYGNPI |
| Myeloma used: | P3X63Ag8.653 |
| Cat. #: | 151837 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Biochemistry;Cancer;Cell biology;Cell signaling and signal transduction;Tissue-specific biology |
| Application: | IHC ; ELISA ; IHC ; WB |
| Target: | TIMP2 (tissue inhibitor of metalloproteinases 2) |
| Reactivity: | Human ; Mouse ; Rat ; Zebrafish |
| Clone: | 3A4 |
| Host: | Mouse |
| Class: | Monoclonal |
| Target background: | Matrix metalloproteinase (MMP) family are involved in the breakdown of extracellular matrix (ECM) in normal physiological processes as well as in disease processes. Tissue inhibitors of metalloproteinases (TIMPs) are the main physiological regulators of the MMPs. The TIMPs are secreted proteins that complex with individual MMPs and regulate the activity of specific MMPs. Together, the MMPs and TIMPs form a complex biological system strictly controlling degradation of ECM. The MMPs and TIMPs have a significant role in facilitating tumour invasion and metastasis. Expression of TIMP2 has been identified in individual studies as prognostic biomarkers in established and locally advanced colorectal cancer. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -80° C |
| Shipping conditions: | Dry ice |
| References: |
Keren-Shaul et al. 2017. Cell. 169(7):1276-1290.e17. PMID: 28602351. A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. Jeffery et al. 2009. Histopathology. 54(7):820-8. PMID: 19635101. The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers. Lyall et al. 2006. Clin Cancer Res. 12(4):1184-91. PMID: 16489072. Profiling markers of prognosis in colorectal cancer. Curran et al. 2004. Clin Cancer Res. 10(24):8229-34. PMID: 15623598. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Murray et al. 1998. Gut. 43(6):791-7. PMID: 9824606. Matrix metalloproteinases and their inhibitors in gastric cancer. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151027 | Anti-HSVICP8 [10A3] |
Key Info
Anti-HSVICP8 [10A3]
|
View Tool | |||||||||||||||||||
| 151036 | Anti-ICAM1 [15.2] |
Key Info
Anti-ICAM1 [15.2]
|
View Tool | |||||||||||||||||||
| 151028 | Anti-Cytochrome P450 2C2, 2B1/2 [h7] |
Key Info
Anti-Cytochrome P450 2C2, 2B1/2 [h7]
|
View Tool | |||||||||||||||||||
| 151038 | Anti-Cytochrome P450 4A2, 4A3 [Clo4] |
Key Info
Anti-Cytochrome P450 4A2, 4A3 [Clo4]
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.